Rubicon Research has announced its acquisition of an 85% equity stake in Arinna Lifesciences, a pharmaceutical marketing company specializing in the central nervous system (CNS) and neuro-psychiatric segments in India, for approximately ₹176 crore. The deal values Arinna at an enterprise value of ₹200 crore on a cash and debt-free basis. This acquisition is expected to enhance Rubicon's strategy in chronic therapies, particularly in the CNS segment, where the company sees significant long-term growth potential. Arinna, established in 2013, operates a diverse portfolio of over 60 brands across various chronic therapies and has reported steady revenue growth, with a turnover of ₹71.5 crore in FY25, up from ₹60.06 crore in FY23. The acquisition is anticipated to be completed within a month, subject to regulatory approvals. Rubicon's CEO, Parag Sancheti, highlighted that this move aligns with their strategy of leveraging mergers and acquisitions to expand into new segments, building on their successful growth in the U.S. market, where revenues increased by over 32 times from FY15 to FY25. Following the announcement, shares of Rubicon Research rose by 5.57%, closing at ₹870.45 on the Bombay Stock Exchange (BSE).